Validation of a Patient Interview for Assessing Reasons for Antipsychotic Discontinuation and Continuation

Overview

Journal Patient Prefer Adherence

Date 2012 Aug 11

PMID 22879738

Citations 2

Authors

Louis S Matza

Glenn A Phillips

Dennis A Revicki

Haya Ascher-Svanum

Karen G Malley

Andrew C Palsgrove

Douglas E Faries

Virginia Stauffer

Bruce J Kinon

A George Awad

Richard Se Keefe

Dieter Naber

Affiliations

Soon will be listed here.

Abstract

Introduction: The Reasons for Antipsychotic Discontinuation Interview (RAD-I) was developed to assess patients' perceptions of reasons for discontinuing or continuing an antipsychotic. The current study examined reliability and validity of domain scores representing three factors contributing to these treatment decisions: treatment benefits, adverse events, and distal reasons other than direct effects of the medication.

Methods: Data were collected from patients with schizophrenia or schizoaffective disorder and their treating clinicians. For approximately 25% of patients, a second rater completed the RAD-I for assessment of inter-rater reliability.

Results: All patients (n = 121; 81 discontinuation, 40 continuation) reported at least one reason for discontinuation or continuation (mean = 2.8 reasons for discontinuation; 3.4 for continuation). Inter-rater reliability was supported (kappas = 0.63-1.0). Validity of the discontinuation domain scores was supported by associations with symptom measures (the Positive and Negative Syndrome Scale for Schizophrenia, the Clinical Global Impression - Schizophrenia Scale; r = 0.30 to 0.51; all P < 0.01), patients' primary reasons for discontinuation, and adverse events. However, the continuation domain scores were not significantly associated with these other indicators.

Discussion: Results support the reliability, convergent validity, and known-groups validity of the RAD-I for assessing patients' reasons for antipsychotic discontinuation. Further research is needed to examine validity of the RAD-I continuation section.

Citing Articles

Residual Effect of Texting to Promote Medication Adherence for Villagers with Schizophrenia in China: 18-Month Follow-up Survey After the Randomized Controlled Trial Discontinuation.

Cai Y, Gong W, He W, He H, Hughes J, Simoni J JMIR Mhealth Uhealth. 2022; 10(4):e33628.

PMID: 35438649 PMC: 9066323. DOI: 10.2196/33628.

Mobile Texting and Lay Health Supporters to Improve Schizophrenia Care in a Resource-Poor Community in Rural China (LEAN Trial): Randomized Controlled Trial Extended Implementation.

Cai Y, Gong W, He H, Hughes J, Simoni J, Xiao S J Med Internet Res. 2020; 22(12):e22631.

PMID: 33258788 PMC: 7738261. DOI: 10.2196/22631.

References

Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J . Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006; 6:8. PMC: 1402287. DOI: 10.1186/1471-244X-6-8. View

Kahn R, Fleischhacker W, Boter H, Davidson M, Vergouwe Y, Keet I . Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618):1085-97. DOI: 10.1016/S0140-6736(08)60486-9. View

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

Pyne J, McSweeney J, Kane H, Harvey S, Bragg L, Fischer E . Agreement between patients with schizophrenia and providers on factors of antipsychotic medication adherence. Psychiatr Serv. 2006; 57(8):1170-8. DOI: 10.1176/ps.2006.57.8.1170. View

Landis J, Koch G . An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977; 33(2):363-74. View

Matza L, Phillips G, Revicki D, Ascher-Svanum H, Malley K, Palsgrove A . Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Res. 2012; 200(2-3):835-42. DOI: 10.1016/j.psychres.2012.05.005. View

Cohen J . Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 2009; 70(4):213-20. DOI: 10.1037/h0026256. View

Barbui C, Kikkert M, Mazzi M, Becker T, Bindman J, Schene A . Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology. 2009; 42(5):311-7. DOI: 10.1159/000232973. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

10.

Bell M, Milstein R, Lysaker P, Cicchetti D . The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992; 180(11):723-8. DOI: 10.1097/00005053-199211000-00007. View

11.

Kinon B, Ascher-Svanum H, Adams D, Chen L . The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J Clin Psychopharmacol. 2008; 28(5):544-9. DOI: 10.1097/JCP.0b013e318185e74a. View

12.

Matza L, Phillips G, Revicki D, Ascher-Svanum H, Kaiser D, Stauffer V . Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. Psychiatry Res. 2011; 189(3):463-8. DOI: 10.1016/j.psychres.2011.05.030. View

13.

Stroup T, McEvoy J, Swartz M, Byerly M, Glick I, Canive J . The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003; 29(1):15-31. DOI: 10.1093/oxfordjournals.schbul.a006986. View

14.

Weiden P, Ross R . Why do patients stop their antipsychotic medications? A guide for families and friends. J Psychiatr Pract. 2005; 8(6):413-6. DOI: 10.1097/00131746-200211000-00014. View

15.

Leucht S, Kane J, Kissling W, Hamann J, Etschel E, Engel R . What does the PANSS mean?. Schizophr Res. 2005; 79(2-3):231-8. DOI: 10.1016/j.schres.2005.04.008. View

16.

Liu-Seifert H, Adams D, Ascher-Svanum H, Faries D, Kinon B . Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer Adherence. 2009; 1:9-17. PMC: 2779124. View

17.

Liu-Seifert H, Adams D, Kinon B . Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005; 3:21. PMC: 1327673. DOI: 10.1186/1741-7015-3-21. View

18.

Haro J, Kamath S, Ochoa S, Novick D, Rele K, Fargas A . The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003; (416):16-23. DOI: 10.1034/j.1600-0447.107.s416.5.x. View

19.

Davis S, Koch G, Davis C, LaVange L . Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull. 2003; 29(1):73-80. DOI: 10.1093/oxfordjournals.schbul.a006993. View

20.

Weiden P . Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68 Suppl 1:12-9. View